Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHAIRMAN AND CEO

CHIEF COMMERCIAL OFFICER

SVP, GEN. COUNSEL & CORP. SEC.

CHIEF MEDICAL OFFICER

CFO AND COO

VP, GEN. COUNSEL & CORP. SEC.

CHIEF FINANCIAL OFFICER

Chief Commercial Officer

VP Gen Counsel and Corp Sec.

Chairman and CEO

Chief Medical Officer

Chief Financial Officer

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	acquired	Premium	Premium	Premium	CHAIRMAN AND CEO
2024-02-20	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-02-20	Premium	sold	Premium	Premium	Premium	SVP, GEN. COUNSEL & CORP. SEC.
2024-02-16	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-16	Premium	sold	Premium	Premium	Premium	CHAIRMAN AND CEO
2024-02-16	Premium	sold	Premium	Premium	Premium	CFO AND COO
2024-01-18	Premium	acquired	Premium	Premium	Premium	SVP, GEN. COUNSEL & CORP. SEC.
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	CHAIRMAN AND CEO
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	CFO AND COO
2024-01-18	Premium	acquired	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2024-01-18	Premium	acquired	Premium	Premium	Premium	-
2023-08-08	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2023-08-08	Premium	sold	Premium	Premium	Premium	SVP, GEN. COUNSEL & CORP. SEC.
2023-08-08	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2023-08-08	Premium	sold	Premium	Premium	Premium	CFO AND COO
2023-08-08	Premium	sold	Premium	Premium	Premium	CHAIRMAN AND CEO
2023-08-07	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER

MRNS - Marinus Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MRNS